Editor's note - Express Pharma

Will regulators catch up in 2020?

Rationalising pharma trade margins seems next on the list

Lupin sells stakes in Kyowa but its not a Sayonara

After sartans and ranitidine, where will NDMA show up next?

Slaying GMP non-compliance woes

Heeding the clarion call for sustainability

Price caps are a band aid hiding larger issues

CDSCO is blowin’ in the wind

Big Pharma to get bigger, but what about patients?

Protect IP to grow GDP